Immunological effects of local low-dose immunotherapy in early stage melanoma patients
Phase 2
Completed
- Conditions
- Clinical stage I-II melanomaCancer
- Registration Number
- ISRCTN63321797
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Patients with histologically proven primary melanoma, who are eligible for a SLN biopsy.
Exclusion Criteria
1. Treated with chemotherapy or immunotherapy in the last ten years
2. Autoimmune diseases
3. Congenital or acquired immunodeficiency
4. Use of immunosuppressive medications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method